Cancer death rates fell for both men and women across the United States from 2019 to 2023, extending a downward trend lasting more than twenty years. Published in the journal Cancer, the 2026 Annual Report to the Nation on the Status of Cancer reveals that accelerated progress against lung cancer drives this sustained mortality decline.
The latest collaborative assessment—compiled by the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), the American Cancer Society, and the North American Association of Central Cancer Registries (NAACCR)—examines cancer death data through 2023 and new diagnosis trends through 2022. While declining tobacco use and improved interventions have successfully reduced overall mortality, rising incidence rates in specific demographics demonstrate that our clinical challenges remain dynamic.
In Plain English: The Clinical Takeaway
- Mortality Decline: Overall cancer death rates for men and women dropped steadily between 2019 and 2023, largely due to fewer deaths from lung cancer.
- Persistent Risk: Despite significant therapeutic gains, lung cancer remains the leading cause of cancer death and the second most common cancer diagnosis in both men and women across the U.S.
- Diagnosis Trends: While overall cancer death rates are falling, new diagnoses rose slightly each year from 2018 to 2022, driven primarily by increases in female breast cancer and male prostate cancer.
Two Decades of Declining Mortality and the Lung Cancer Driver
The new findings confirm that the steady drop in cancer mortality is not a temporary fluctuation. It represents a multi-decade epidemiological trend. The primary catalyst behind this improvement is accelerated progress against lung cancer. Reductions in cigarette smoking prevalence and the establishment of tobacco-free environments have significantly shifted the natural history of this malignancy over the first quarter of the 21st century.
However, clinical vigilance remains necessary. Lung cancer continues to be the leading cause of cancer-related mortality in the U.S. and the second most common cancer overall. Authors of the report emphasize that sustaining these hard-won survival gains depends heavily on expanding clinical access. Early cancer detection methods, timely diagnostic workups, and state-of-the-art treatment regimens are vital to reach populations currently missing out on preventative care.
Shifts in Diagnosis Rates: Breast and Prostate Cancers
While mortality figures show consistent improvement, incidence data presents a more complex picture. The report tracked new U.S. cancer cases from 2003 to 2022, revealing that overall diagnosis rates rose slightly each year from 2018 to 2022. This upward trajectory in new cases is driven predominantly by increases in breast cancer among women and prostate cancer among men.
Breast cancer and prostate cancer remain the most common malignancies diagnosed within their respective demographic groups. Interestingly, despite the continued rise in prostate cancer diagnoses, the overall rate of new cancer cases among men remained stable.
| Metric Category | Observed Trend | Timeframe | Primary Driving Factors |
|---|---|---|---|
| Cancer Mortality | Decreased for both men and women | 2019–2023 | Accelerated progress against lung cancer; smoking reductions |
| New Cancer Diagnoses | Rose slightly each year overall | 2018–2022 | Increases in female breast cancer and male prostate cancer |
| Lung Cancer Status | Leading cause of cancer death | Current baseline | Requires expanded early detection and timely diagnostic access |
Collaborative Surveillance and Institutional Methodology
The Annual Report to the Nation is produced through an ongoing collaborative effort among four key public health organizations. These include the CDC, the National Cancer Institute (part of the National Institutes of Health), the American Cancer Society, and NAACCR. The analysis relies on robust data collection infrastructures, utilizing cancer registry data supported by the CDC and NCI, compiled by NAACCR, and integrated with national mortality statistics compiled by the CDC’s National Center for Health Statistics.
Contraindications & When to Consult a Doctor
Timely diagnostic evaluation remains the cornerstone of effective cancer intervention.
References
- Henley, S. J., et al. (2026). Annual Report to the Nation on the Status of Cancer, featuring 21st century progress against lung cancer. Cancer.
- Centers for Disease Control and Prevention (CDC). Annual Report to the Nation: Progress Against Lung Cancer Drives Down Cancer Mortality.
- National Cancer Institute (NCI).
